Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07349173

Peripersonal Space Representation in Upper Limb Segmental Exclusion

This study aims to evaluate the representation of action peripersonal space (PPS) in subjects suffering from unilateral segmental exclusion syndrome of the upper limb compared to healthy control subjects. Segmental exclusion is defined by non-use or under-use of a limb segment without central nervous system damage. The study hypothesizes that this syndrome leads to a modification (shrinkage) of the PPS representation. Participants will perform reachability judgments in a Virtual Reality (VR) environment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut Régional de Médecine Physique et de Réadaptation (IRR), Centre Louis Pierquin.

Nancy, 54000, France

Location status: Recruiting

Location contact

Jonathan Pierret, PhD

CONTACT

[email protected]

+33 3 83 52 67 61

About this study

Segmental exclusion syndrome often occurs after limb trauma and manifests as a neglect-like behavior of peripheral origin, sometimes associated with Complex Regional Pain Syndrome (CRPS). The study explores whether the lack of limb use affects the representation of peripersonal space (PPS)-the space immediately surrounding the body where interactions with objects occur.

The study is monocentric, observational, with a matched control group. Participants will undergo:

Clinical assessment (questionnaires on pain, anxiety, body perception, and kinesiophobia).

A Virtual Reality (VR) test (approx. 40 minutes). In VR, participants will judge whether a cylinder presented at different distances and angles is reachable without moving (Perceived Reachable Distance - DMA-p). This will be compared to their Real Reachable Distance (DMA-r).

The goal is to measure the error of judgment to assess PPS representation and check for correlations with body schema disturbances or functional impairment

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(patients):

  • Age ≥ 18 years.
  • Presenting unilateral exclusion symptom of the upper limb or part of the hand evolving for > 3 months.
  • No contraindication to force work in daily activities.
  • For patients with finger exclusion: at least 2 perturbed items related to exclusion on tests 3 and 4 of the "Bilan 400 points".
  • Affiliated to a social security scheme.
  • Able to understand simple orders.

Inclusion criteria

(Controls):

  • Age ≥ 18 years.
  • No history of upper limb impairment with sequelae.

Exclusion criteria

(All):

  • Visual impairments.
  • Central neurological pathology.
  • Unstabilized psychiatric pathology.
  • Communication or comprehension difficulties.
  • Under legal protection or unable to consent.
  • Pregnant or breastfeeding women.
  • Cervical pathology contraindicating VR headset use.
  • Epilepsy.
  • Upper limb pathology unrelated to exclusion.
  • Inability to stand for 40 minutes.

Treatment and study plan

Reachability Judgment Task in VR.

Behavioral

Participants wear an Oculus Quest 2 VR headset. They first perform a motor task to measure Real Reachable Distance (DMA-r). Then, they perform a perceptual task where they must judge, without moving, if a virtual object is reachable (DMA-p). The test evaluates different spatial planes (front, 45° right, 45° left) and heights (shoulder, navel).

Primary outcomes

  1. Judgment Error of Reachability

    Time frame: Day 1 (During the 40-minute VR assessment)

    The Judgment Error of Reachability is a single composite metric calculated as: ((DMA-p - DMA-r) / DMA-r) × 100, expressed as a percentage (%).

    Both DMA-p (Perceived Maximum Reachable Distance) and DMA-r (Real Maximum Reachable Distance) are measured in centimeters, and their ratio yields a single dimensionless percentage score.

Secondary outcomes

  1. Body Perception Disturbance Score

    Time frame: Day 1 (Before VR task)

    Assessed using the Bath CRPS Body Perception Disturbance Scale (French version). Scores range from 0 to 57, with higher scores indicating greater disturbance.

  2. Functional Impairment Score (400-Point Hand Assessment)

    Time frame: Day 1

    Evaluated using the 400-Point Hand Assessment, which measures functional hand use. The score ranges from 0 to 400, where higher scores indicate better functional performance (better outcome).

  3. Anxiety and Depression Score (HAD)

    Time frame: Day 1

    Hospital Anxiety and Depression Scale. Scores range from 0 to 21 for each dimension (Anxiety and Depression).

  4. Kinesiophobia Score (Tampa Scale)

    Time frame: Day 1

    Tampa Scale for Kinesiophobia (TSK). Assesses fear of movement. Scores range to 68; >40 indicates significant kinesiophobia.

  5. Pain Catastrophizing Score (PCS)

    Time frame: Day 1

    Pain Catastrophizing Scale. Scores range from 0 to 52.

Study contacts

Contact information is provided by the study sponsor or research team.

Amélie Touillet, MD

CONTACT

[email protected]

+33 3 83 52 98 80

Jonahtan Pierret, PhD

CONTACT

[email protected]

+33 3 83 52 67 61

Sponsors and collaborators

Lead sponsor

Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est

Other

Registry information

Official study title

Study of the Representation of Action Peripersonal Space in Participants With Unilateral Segmental Exclusion of the Upper Limb Compared to Asymptomatic Subjects

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Jan 16, 2026
Registry last updated
Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.